Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

J&J In-Licenses Immune Adjuvant from Sino Biopharma

publication date: Jan 7, 2016
Johnson & Johnson in-licensed ex-China rights to immune-modulating agents from a Sino Biopharma subsidiary, which it intends to use as part of a regimen for hepatitis B. Recently, J&J acquired Novira Therapeutics, a privately held US biopharma whose lead drug treats HBV. J&J plans to combine Novira's NVR 3-778, an oral small molecule direct acting antiviral that inhibits the HBV capsid protein, and Sino Biopharma's immune system adjuvant. The company hopes the combination will cure HBV, as opposed to current products that require life-long treatment. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital